NGS based Companion Ultra-Sensitive Minimal Residual Disease (MRD) Tracking Service for CAR Therapy

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite the transformative potential of CAR therapies, their clinical success is often hindered by challenges in accurately monitoring minimal residual disease (MRD) and distinguishing true remission from impending relapse due to insufficient sensitivity and tumor heterogeneity. Our NGS-based companion ultra-sensitive MRD tracking platform addresses these gaps by leveraging high-depth sequencing and personalized tumor-informed panels to detect circulating tumor DNA with exceptional precision. This service offers end-to-end longitudinal monitoring, from baseline profiling to post-infusion follow-up, with rapid turnaround and comprehensive bioinformatics support.

Introduction

Minimal residual disease (MRD) represents the persistence of malignant cells at levels below the detection threshold of conventional morphology, serving as the most powerful independent predictor of relapse and long-term survival outcomes across hematological malignancies. Our NGS-based companion ultra-sensitive MRD platform delivers a transformative analytical framework for CAR-T therapies, integrating clonal fingerprinting, personalized mutation tracking, and phased haplotype analysis to achieve detection sensitivities down to one cell per million, thereby enabling real-time therapeutic response monitoring, early molecular relapse detection, and informed clinical decision-making throughout the entire patient treatment journey.

Fig.1 The advancement of MRD-driven cancer care entails a fundamental move from conventional analog therapeutic regimens to comprehensive digital longitudinal tracking systems. (OA Literature) Fig.1 The evolution of MRD-guided cancer management reflects a shift from conventional, analog treatment approaches to dynamic, digital longitudinal surveillance.¹

Our Service

Elevate your cellular therapy pipeline with our NGS-Based Companion Ultra-Sensitive MRD Tracking. Designed specifically for CAR-T/NK therapeutics, this high-precision platform detects minimal residual disease at an unprecedented sensitivity. By offering robust clinical endpoints and early relapse detection, we empower drug developers and clinicians with actionable insights to accelerate trials and optimize patient management.

What We Can Offer

Our platform delivers a comprehensive, ultra-sensitive NGS-based MRD tracking ecosystem for CAR-T therapies, integrating clinically validated clonal fingerprinting, personalized mutation surveillance, and high-fidelity haplotype analysis to empower precise response assessment, early relapse prediction, and strategic intervention guidance.

Featured services of NGS-based companion ultra-sensitive MRD tracking for CAR therapies at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Baseline Sample.
Monitoring Sample.
Control Sample.
CAR Transgene Reference Sequence.

Key Steps:

Workflow of NGS-based companion ultra-sensitive MRD tracking for CAR therapies at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

MRD Quantitative Report.
Data Package.

Key Advantages

Dual-Target Kinetic Monitoring of Tumor and CAR Cells: The assay simultaneously quantifies endogenous malignant clones and exogenous CAR gene persistence, providing critical kinetic data to guide timely secondary infusions or combination therapies.
High Specificity to Overcome Antigen Escape: By tracking unique intracellular clonal sequences at the nucleic acid level, it circumvents the false negatives caused by tumor surface antigen loss that frequently compromise flow cytometry.
Companion Diagnostics for Precision Patient Stratification: Serving as a powerful prognostic indicator at key post-infusion milestones, it enables clinicians to dynamically stratify patient risk and tailor personalized interventions, avoiding overtreatment while intercepting high-risk progression early.

FAQ

Q1: Does antigen escape compromise the assay's performance?

A1: Not at all. Conventional flow cytometry relies heavily on surface markers, making it susceptible to false negatives when tumors downregulate these targets. In contrast, our platform operates at the nucleic acid level by tracking patient-specific clonal V(D)J rearrangements. This genetic-level anchoring guarantees flawless tumor cell identification and quantification, completely independent of surface protein expression.

Q2: What is the underlying mechanism for the concurrent tracking of tumor clones and CAR cells?

A2: This dual-monitoring capability is achieved through an integrated multiplex PCR or hybrid-capture sequencing architecture. By embedding probes and primers for both endogenous malignant rearrangements and exogenous CAR transgene constructs within a single assay system, the platform simultaneously delivers synchronized readouts of the patient's MRD burden alongside real-time CAR-T expansion and persistence kinetics.

Why Choose Us?

We combine ultra-sensitive NGS-based ctDNA detection with personalized tumor-informed panels to deliver unmatched MRD surveillance for CAR therapies. Our end-to-end longitudinal monitoring, rapid turnaround, and expert bioinformatics support enable early relapse prediction and actionable clinical insights, empowering precise, timely interventions that directly improve patient outcomes.

Customer Reviews

"Implementing this ultra-sensitive NGS MRD tracking service as a companion tool in our Phase II CAR-T trials has been a game-changer. Standard flow cytometry simply lacked the depth required to catch early molecular relapses. With this platform's deep sequencing capabilities, we could detect clonal kinetic shifts weeks before clinical symptoms appeared." Dr. A* T*.

"What sets this NGS service apart is its seamless integration as a companion diagnostic. The turnaround time is incredibly efficient for a high-throughput genomic assay, and the bioinformatics pipeline translates complex sequencing data into clear, actionable reports." M* V*, PhD

How to contact us?

Ready to elevate your CAR therapy trials with ultra-sensitive MRD intelligence? Reach out to our scientific liaison team for a confidential consultation. We offer tailored discussions on assay design, validation strategies, and scalable monitoring plans. Let's explore how our precision platform can accelerate your clinical development—inquire today for a customized proposal.

Reference

Kim, Jinhee et al. "Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient Management." Cancers vol. 18,7 1049. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cancers18071049.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.